Table 2.
Clinico‐pathological findings of isolated STIC detected at RRSO
| Reference | Cases of STIC (STIC/RRSO) | Median age (range) | BRCA status (BRCA1 mt/BRCA2 mt) | Cytology at RRSO (negative/positive) | Surgery at or after RRSO | Chemotherapy | Follow up after RRSO in months (range) | Subsequent cancer |
|---|---|---|---|---|---|---|---|---|
| Finch et al62 | 1/159 (0.6%) | 64 | 1/0 | 1/0 | TH + OMT (1) | NR (1) | NR | NR (1) |
| Carcangju et al63 | 3/50 (6%) | 53 (48‐61) | 3/0 | 2/0, NR (1) | TH (1) | ND (3) | 44 (7‐87) | None (3) |
| Lamb et al64 | 4/113 (3.5%) | 53 (46‐65) | 2/2 | 3/1 | staging (1), ND (3) | C/P (2), ND (2) | NR | None (4) |
| Medeiros et al21 | 3/26 (11.5%) | 51 (43‐66) | 1/2 | 2/1 | TH (3), Staging (3) | NR (3) | NR | NR (3) |
| Callahan et al65 | 3/122 (2.5%) | 51 (44‐66) | 1/2 | 2/1 | TH (3), Node (2) | C/P (3) | NR | None (3) |
| Shaw et al66 | 15/176 (8.5%) | NR | 8/7 | NR (15) | NR | NR (15) | NR | NR (15) |
| Manchanda et al67 | 6/308 (1.9%) | 53 (44‐67) | 3/1, unknown (2) | 6/0 | ND (6) | ND (6) | NR | NR (6) |
| Mingels et al68 | 14/226 (6.2%) | NR | 9/5 | NR (14) | NR | NR (14) | NR | NR (14) |
| Powel et al69 | 16/407 (3.9%) | 56 (46‐76) | 12/4 | 13/3 | Staging (9) | C/P (4), ND (12) | 81 (40‐150) | PPC 1, None (15) |
| Reitsma et al70 | 3/360 (0.8%) | 54 (50‐57) | 0/2 (+VUS1) | 3/0 | ND (3) | NR (3) | 12 (2‐26) | None (3) |
| Wethington et al22 | 12/593 (2%) | 54 (39‐77) | 5/5, unknown (2) | 11/1 | TH (7), OMT (7), Biopsy (9), Node (6) | ND (12) | 28 (16‐44) | None (12) |
| Conner et al71 | 11/349 (3.2%) | 49 (31‐60) | 5/1, BRCA1 or 2 (5) | 7/NR (4) | Staging (3) | C/P (2), ND (9) | 60 (12‐96) | Elevated CA125 and ascites (1), None (10) |
| Sharman et al72 | 4/966 (0.4%) | 54 (28‐58) | 2/2 | 4/0 | ND (4) | NR (4) | NR | NR (4) |
| Zakour et al73 | 9/246 (3.7%) | 57 (36‐76) | 8/1 | 9/0 | TH (2), NR (7) | ND (9) | 79 (25‐138) | PPC (2) None (7) |
| Poon et al74 | 3/72 (4.2%) | 52 (range NR) | 2/1 | 1/1, NR (1) | ND (3) | ND (3) | 79 (45‐108) | None (3) |
| Miller et al75 | 3/70 (4.3%) | NR | 3/0 | 3/0 | Peritoneal and Omental biopsy (3) | NR (3) | NR | None (3) |
| Lee et al76 | 2/36 (5.6%) | 51 (range NR) | 1/1 | NR (2) | NR (2) | NR (2) | NR | NR (2) |
| Total | 112/4279 (2.6%) | 54 (31‐77) | 66/36 (+VUS1), unknown 9 | Positive ratio 8/75 (10.7%) | TH 15/72 (20.5%) OMT 8/72 (11.1%) staging 16/72 (22.2%) node 8/72 (11.1%) biopsy 12/72 (16.7%) | C/P 11/67 (16.4%) | (2‐150) | PPC 3/67 (4.5%) |
Abbreviations: C/P, carboplatin‐paclitaxel; mt, mutation; ND, not done; Node, retroperitoneal lymphadenectomy; NR, not recorded; OMT, omentectomy; PPC, primary peritoneal cancer; RRSO, risk‐reducing bilateral salpingo‐oophorectomy; STIC, serous tubal intraepithelial carcinoma; TH, total hystecrtomy; VUS, variant of uncertain significance.